Login to Your Account

Phase III Plans in the Works

Cytokinetics’ Phase II HF Data: Traders Skeptical, Amgen Not

By Randy Osborne
Staff Writer

Wednesday, September 4, 2013
Cytokinetics Inc. and licensor Amgen Inc. will wait until a Phase II study in chronic heart failure with orally given omecamtiv mecarbil generates data to decide the fate of the compound, which fizzled in a Phase II trial testing the intravenous (I.V.) form of the cardiac myosin activator against acute heart failure (AHF).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription